唑来膦酸治疗对雌二醇和倍他米松耐药的转移性激素难治性前列腺癌的血清pSa水平正常化

Central European Journal of Urology 1\/2010 Pub Date : 1900-01-01 DOI:10.5173/CEJU.2009.02.ART14

Kensaku Seike, Y. Asaeda, Naoki Yamamoto, S. Maeda

{"title":"唑来膦酸治疗对雌二醇和倍他米松耐药的转移性激素难治性前列腺癌的血清pSa水平正常化","authors":"Kensaku Seike, Y. Asaeda, Naoki Yamamoto, S. Maeda","doi":"10.5173/CEJU.2009.02.ART14","DOIUrl":null,"url":null,"abstract":"We present a 78-year-old male with hormone-refractory prostate cancer (HRPC), who obtained complete long term regression of prostate specific antigen level during zoledronic acid (ZA) therapy. Our case suggests clinical utility of ZA in managing some of HRPC patients.","PeriodicalId":133584,"journal":{"name":"Central European Journal of Urology 1\\/2010","volume":"218 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"normalization of serum pSa level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone\",\"authors\":\"Kensaku Seike, Y. Asaeda, Naoki Yamamoto, S. Maeda\",\"doi\":\"10.5173/CEJU.2009.02.ART14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We present a 78-year-old male with hormone-refractory prostate cancer (HRPC), who obtained complete long term regression of prostate specific antigen level during zoledronic acid (ZA) therapy. Our case suggests clinical utility of ZA in managing some of HRPC patients.\",\"PeriodicalId\":133584,\"journal\":{\"name\":\"Central European Journal of Urology 1\\\\/2010\",\"volume\":\"218 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Central European Journal of Urology 1\\\\/2010\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5173/CEJU.2009.02.ART14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Urology 1\\/2010","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5173/CEJU.2009.02.ART14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

我们报告了一位78岁男性激素难治性前列腺癌(HRPC)患者，他在唑来膦酸(ZA)治疗期间获得了前列腺特异性抗原水平的完全长期消退。我们的病例提示ZA在治疗一些HRPC患者中的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

normalization of serum pSa level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone

We present a 78-year-old male with hormone-refractory prostate cancer (HRPC), who obtained complete long term regression of prostate specific antigen level during zoledronic acid (ZA) therapy. Our case suggests clinical utility of ZA in managing some of HRPC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

$Central European Journal of Urology 1\/2010$

Central European Journal of Urology 1\/2010

自引率

0.00%

发文量